TransCode Therapeutics Inc (RNAZ)
1.14
+0.26
(+28.84%)
USD |
NASDAQ |
May 17, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
TransCode Therapeutics Free Cash Flow (Quarterly): 10.13M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.13M |
| September 30, 2023 | -3.510M |
| June 30, 2023 | -4.410M |
| March 31, 2023 | -4.526M |
| December 31, 2022 | 8.107M |
| September 30, 2022 | -4.422M |
| June 30, 2022 | -3.414M |
| March 31, 2022 | -3.979M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.676M |
| September 30, 2021 | -3.140M |
| June 30, 2021 | -0.0982M |
| March 31, 2021 | -0.5975M |
| December 31, 2020 | -0.2555M |
| September 30, 2020 | -0.1308M |
| June 30, 2020 | -0.0885M |
| March 31, 2020 | -0.0181M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-4.526M
Minimum
Mar 2023
10.13M
Maximum
Dec 2023
-0.5422M
Average
-0.4265M
Median
Free Cash Flow (Quarterly) Benchmarks
| Citius Pharmaceuticals Inc | -7.786M |
| NovaBay Pharmaceuticals Inc | -1.574M |
| Palatin Technologies Inc | -8.607M |
| iBio Inc | -4.706M |
| Theriva Biologics Inc | -4.881M |